Inhalers used to treat symptoms of respiratory disease can be potent sources of greenhouse gases. Drugmakers are planning to ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

GSK said data from a late-phase study showed that its respiratory syncytial virus vaccine, Arexvy, granted protection over three full RSV seasons.

Pfizer’s victory in London court invalidates two GSK patents for respiratory syncytial virus (RSV) vaccine. GSK plans to ...